The 18th Golden Helix Pharmacogenomics day will be organized in the lecture hall of the IMT Institute of advanced studies in Lucca, Italy. The meeting will be co-organized from the University of Pisa and the Golden Helix Foundation.
The search for biomarkers is increasingly required in many disciplines: in cancer, to assess the response to treatment and risk of treatment-related toxicity, as well as in transplants to monitor the graft injury.Significant achievements have been made in our understanding and clinical application of pharmacogenetics in cancer of drug-metabolising enzymes in order to predict fluoropyrimidine- and irinotecan-related toxicities with the screening of DPYD and UGT genes, respectively. Circulating tumour DNA could represent a powerful diagnostic tool to help clinical decision making, as it is being used, at least for research purposes, to assess tumour heterogeneity, identify genetic determinants for targeted therapy, evaluate the response to treatment and assess the evolution of molecular resistance over time. Moreover, the field of solid organ transplantation has been seeing improved graft outcomes, with reduced rates of acute rejection due to the use of immunosuppressive drugs (tacrolimus, cyclosporine, MMF). However, the diagnostic tools available to monitor the transplant rejection are costly, have the danger of complications or are available too late for the patient. A new and innovative approach for detecting organ rejection makes use of plasma graft-derived cell free DNA in the recipient, arising from damaged cells when the transplanted donor organ is subject to rejection. However, the choice of genetic markers and the implementation of new technologies in clinical practice should be discussed between the main stakeholders.
The 18th Golden Helix Pharmacogenomics Day and the satellite “Young Biomarkers Day” that will precede the main event will address these important issues by involving young researchers and expert scientists, with the aim of discussing the appropriate use of technological platforms and molecular biomarkers in transplants and in solid tumours (i.e. colorectal, lung, breast cancer and melanoma), especially in the era of new therapeutic options (i.e. immunotherapy, monoclonal antibodies and new immunosoppressive drugs). This conference is open for general pharmacists, specialists, general practitioners, medical and pharmacy students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
On behalf of the Organizing Committee
Co-organized by:
Under the auspices of:
IntroductionSpeakersSatellite EventScientific ProgramSponsorsThe 18th Golden Helix Pharmacogenomics day will be organized in the lecture hall of the IMT Institute of advanced studies in Lucca, Italy. The meeting will be co-organized from the University of Pisa and the Golden Helix Foundation.
The search for biomarkers is increasingly required in many disciplines: in cancer, to assess the response to treatment and risk of treatment-related toxicity, as well as in transplants to monitor the graft injury.Significant achievements have been made in our understanding and clinical application of pharmacogenetics in cancer of drug-metabolising enzymes in order to predict fluoropyrimidine- and irinotecan-related toxicities with the screening of DPYD and UGT genes, respectively. Circulating tumour DNA could represent a powerful diagnostic tool to help clinical decision making, as it is being used, at least for research purposes, to assess tumour heterogeneity, identify genetic determinants for targeted therapy, evaluate the response to treatment and assess the evolution of molecular resistance over time. Moreover, the field of solid organ transplantation has been seeing improved graft outcomes, with reduced rates of acute rejection due to the use of immunosuppressive drugs (tacrolimus, cyclosporine, MMF). However, the diagnostic tools available to monitor the transplant rejection are costly, have the danger of complications or are available too late for the patient. A new and innovative approach for detecting organ rejection makes use of plasma graft-derived cell free DNA in the recipient, arising from damaged cells when the transplanted donor organ is subject to rejection. However, the choice of genetic markers and the implementation of new technologies in clinical practice should be discussed between the main stakeholders.
The 18th Golden Helix Pharmacogenomics Day and the satellite “Young Biomarkers Day” that will precede the main event will address these important issues by involving young researchers and expert scientists, with the aim of discussing the appropriate use of technological platforms and molecular biomarkers in transplants and in solid tumours (i.e. colorectal, lung, breast cancer and melanoma), especially in the era of new therapeutic options (i.e. immunotherapy, monoclonal antibodies and new immunosoppressive drugs). This conference is open for general pharmacists, specialists, general practitioners, medical and pharmacy students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
On behalf of the Organizing Committee
Co-organized by:
Under the auspices of:
Organizing Committee
Romano Danesi, Professor, University of Pisa, Pisa, Italy
George P. Patrinos; Associate Professor; University of Patras Department of Pharmacy. Patras, Greece
Marzia Del Re, Researcher, University of Pisa, Pisa, Italy
Invited speakers and moderators
Guillem Argils Martnez, Barcelona, ES
Carlotta Antoniotti, Pisa, IT
Massimo Mario Augello, Pisa, IT
Ugo Boggi, Pisa, IT
Franco Citterio, Rome, IT
Chiara Cremolini, Pisa, IT
Romano Danesi, Pisa, IT
Marzia Del Re, Pisa, IT
Massimo Di Maio, Turin, IT
Antonello Di Paolo, Pisa, IT
Eva Dreussi, Aviano, IT
Alfredo Falcone, Pisa, IT
Simone Ferrero, Turin, IT
Gabriella Fontanini, Pisa, IT
Sara Galimberti, Pisa. IT
Isaac Garcia-Murillas, London, UK
Dennis Hesselink, Rotterdam, NL
Guido Jenster, Rotterdam, NL
Niki Karachaliou, Barcelona, ES
Matteo Lambertini, Genoa, IT
Francesco Massari, Malpighi, IT
George P. Patrinos, Patras, GR
Iacopo Petrini, Pisa, IT
Mario Petrini, Pisa, IT
Sara Pilotto, Verona, IT
Rafael Rosell, Barcelona, ES
Aldo Scarpa, Verona, IT
Carlo Rinaldo Tomassini, Pisa, IT
Ron H. van Schaik, Rotterdam, NL
Scientific Program – Young Biomarkers Day – 15 June 2016
10:00-10:30 Welcome addresses
Piero Pietrini, Director of IMT School for Advanced Studies Lucca
Massimo Mario Augello, Chancellor, University of Pisa
Carlo Rinaldo Tomassini, General Director, University Hospital
Mario Petrini, Director of Department of Clinical and Experimental Medicine
Romano Danesi, Director of Department of Laboratory Medicine
SESSION I Chairmen: S. Galimberti, R. Danesi
10:30-11:00 Ron H. van Schaik, Professor; Erasmus University Medical Center, Department of Clinical Chemistry; Rotterdam, the Netherlands
Pharmacogenomics data: clinical application in oncology
11:00-11:30 Massimo Di Paolo, Professor, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Pharmacokinetic modeling incorporating Pharmacogenomics data: clinical application in hematology
11:30-12:00 Coffee break
SESSION II Chairmen: M. Del Re, F. Massari
12:00-12:30 Massimo Di Maio, Professor, Department of Oncology, University of Torino, Torino, Italy
Clinical trials for the study of biomarkers: from classical to innovative designs
12:30-13:00 Sara Pilotto, Researcher, University of Verona , Azienda Ospedaliera Universitaria Integrata, Verona , Italy
Clinical trial design: how to validate circulating nucleic acids?
13:00-14:30 Lunch break
SESSION III Chairmen: M. Di Maio & C. Cremolini
14:30-15:00 Carlotta Antoniotti, Researcher, Division of Medical Oncology , Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Clinical case I Circulating nucleic acids in Common Record CommonLine
15:00-15:30 Iacopo Petrini, Researcher, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
Clinical case II Circulating nucleic acids in Non-Small Cell Lung Cancer
15:30-16:00 Matteo Lambertini, Researcher, Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
Clinical case III Circulating nucleic acids in Mucinous breast carcinoma
16:00-16:30 Coffee break
16:30-17:00 Eva Dreussi, Researcher, Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
Incorporating Pharmacogenomics into clinical practice – The role of the pharmacologist
17:00-17:30 Enrico Vasile, Researcher, Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria, Pisa, Italy
Incorporating Pharmacogenomics into clinical practice – The interest of the oncologist
Scientific Program – 16 June 2016
8:00 Registration
09.00 – 09.30 Welcome addresses
Romano Danesi, Professor, University of Pisa, Pisa, Italy
George P. Patrinos; Associate Professor; University of Patras Department of Pharmacy, Patras, Greece
SESSION I Chairmen: F. Citterio & U. Boggi
09.30 – 10.00 George P. Patrinos; Associate Professor; University of Patras Department of Pharmacy, Patras, Greece
Pharmacogenomics in the era of Precision Medicine
10.00 – 10.30 Ron H van Schaik; Professor; Erasmus MC, Department of Clinical Chemistry, Rotterdam, the Netherlands
How and when to monitor CNAs in transplantation
10.30 – 11.00 Dennis A. Hesselink; Internist-Nephrologist; Erasmus MC, Department of Internal Medicine Division of Nephrology and Kidney Transplantation University Medical Center Rotterdam, The Netherlands
Clinical applications of CNAs in renal transplant
11.00 – 11.30 Coffee break
SESSION II Chairmen: G. Fontanini & A. Falcone
11.30 – 12.00 Romano Danesi; Professor, University of Pisa, Pisa, Italy
How and when to monitor CNAs in oncology
12.30 – 12.30 Aldo Scarpa; Director, ARC-Net Research Centre at University of Verona, Verona, Italy
Pros and cons of tissue vs CNAs
12.30 – 12.50 Astrid Kiermaier / Roberto Scalamogna; Roche Pharmaceuticals
The future of Personalize Health Care: The Biotech experience
12.50 – 14.30 Lunch
SESSION III Chairmen: R. Rosell & G. Masi
14.30 – 15.00 Niki Karachaliou, Researcher; Translational Research Group in Pangaea Biotech, USP Instituto Universitario Dexeus, Barcelona, Spain
Clinical applications of CNAs in NSCLC
15.00 – 15.30 Chiara Cremolini; Ph.D, candidate; University of Pisa, Pisa, Italy
Clinical applications of CNAs in colorectal cancer
15.30 – 16.00 Isaac Garcia-Murillas; Researcher; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
Clinical applications of CNAs in breast cancer
16.00 – 16.30 Coffee break
SESSION IV Chairmen: R. van Schaik & S. Galimberti
16.30 – 17.00 Guido Jenster,Professor of Experimental Urological Oncology, Department of Urology, Experimental Urology Research Laboratory Josephine Nefkens Institute, Erasmus MC Rotterdam, The Netherlands
Clinical applications of CNAs in prostate cancer
17.00 – 17.30 Simone Ferrero,Researcher, Department of Molecular Biotechnology and Health Sciences University of Torino, Torino, Italy
Clinical applications of CNAs in haematologic malignancies
17.30 – 18.00 Guillem Argils Martnez, Clinical Investigator, Gastrointestinal Malignancies Program Early Drug Development Program Vall dHebron University Hospital, Vall d’Hebron Institute of Oncolgy (VHIO)
Are we ready for prime time use?
18.00 – 18.30 Conclusions
Sponsors
The Organizing Committee acknowledges the support of following entities that support the organization of the 18th Golden Helix Pharmacogenomics Day:
Sponsors
Provider ECM-316
